Current Developmental Disorders Reports

, Volume 5, Issue 2, pp 101–107 | Cite as

Standard, Complementary, and Future Treatment Options for Tics

  • April N. Sharp
  • Harvey S. Singer
Tourette's Syndrome (TS Zeiger, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Tourette’s Syndrome


Purpose of Review

Tics occur in up to 20% of children and are a defining feature of Tourette syndrome (TS). When treatment is necessary, there are many options available. The purpose of this review is to present an overview of the standard, complementary/alternative medicine (CAM), and emerging treatments of tics and provide examples of the current evidence supporting these therapies.

Recent Findings

Behavioral therapy and conventional pharmacotherapy are the mainstays of treatment and have the strongest evidence to support their use. CAM is common, but there are few rigorous randomized, controlled trials evaluating the safety and efficacy of these modalities. Several novel pharmacological and nonpharmacological treatments targeting specific pathways thought to be involved in TS are currently being studied with the hope of expanding future treatment options.


We conclude that there is an ongoing need for new evidence-based approaches for safe and effective treatment of tics.


Tics Tourette syndrome Placebo effect Complementary/alternative medicine CAM 


Compliance with Ethical Standards

Conflict of Interest

April N. Sharp reports no conflict of interest.

Harvey S. Singer reports grants from Tourette Association of America.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Kurlan R, McDermott MP, Deeley C, Como PG, Brower C, Eapen S, et al. Prevalence of tics in schoolchildren and association with placement in special education. Neurology. 2001;57(8):1383–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Robertson MM. A personal 35 year perspective on Gilles de la Tourette syndrome: prevalence, phenomenology, comorbidities, and coexistent psychopathologies. Lancet Psychiatry. 2015;2(1):68–87.PubMedCrossRefGoogle Scholar
  3. 3.
    Robertson MM. The prevalence and epidemiology of Gilles de la Tourette syndrome. Part 1: the epidemiological and prevalence studies. J Psychosom Res. 2008;65(5):461–72.PubMedCrossRefGoogle Scholar
  4. 4.
    Kompoliti K, Fan W, Leurgans S. Complementary and alternative medicine use in Gilles de la Tourette syndrome. Mov Disord. 2009;24(13):2015–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Mantel BJ, Meyers A, Tran QY, Rogers S, Jacobson JS. Nutritional supplements and complementary/alternative medicine in Tourette syndrome. J Child Adolesc Psychopharmacol. 2004;14(4):582–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Piacentini J, Woods DW, Scahill L, Wilhelm S, Peterson AL, Chang S, et al. Behavior therapy for children with Tourette disorder: a randomized controlled trial. JAMA. 2010;303(19):1929–37.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Wilhelm S, Peterson AL, Piacentini J, Woods DW, Deckersbach T, Sukhodolsky DG, et al. Randomized trial of behavior therapy for adults with Tourette syndrome. Arch Gen Psychiatry. 2012;69(8):795–803.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Himle MB, Freitag M, Walther M, Franklin SA, Ely L, Woods DW. A randomized pilot trial comparing videoconference versus face-to-face delivery of behavior therapy for childhood tic disorders. Behav Res Ther. 2012;50(9):565–70.PubMedCrossRefGoogle Scholar
  9. 9.
    Singer HS. Treatment of tics and tourette syndrome. Curr Treat Options Neurol. 2010;12(6):539–61.PubMedCrossRefGoogle Scholar
  10. 10.
    •• Thenganatt MA, Jankovic J. Recent advances in understanding and managing tourette syndrome. F1000Res. 2016 5. Pii: F1000 faculty Rev-152. This article details current understanding of pathophysiology of TS and targeted therapies. Google Scholar
  11. 11.
    •• Ganos C, Martino D, Pringsheim T. Tics in the pediatric population: pragmatic management. Mov Disord Clin Pract. 2017;4(2):160–72. This review provides a comprehensive treatment guide for pediatric tics and includes a helpful flowsheet. PubMedCrossRefGoogle Scholar
  12. 12.
    Scahill L, Erenberg G, Berlin CM Jr, Budman C, Coffey BJ, Jankovic J, et al. Tourette syndrome association medical advisory board: practice committee. Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx. 2006;3(2):192–206.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    •• Whittington C, Pennant M, Kendall T, Glazebrook C, Trayner P, Groom M, et al. Practitioner review: treatments for tourette syndrome in children and young people—a systematic review. J Child Psychol Psychiatry. 2016;57(9):988–1004. This is a systematic review comparing the evidence for standard treatments of TS. PubMedCrossRefGoogle Scholar
  14. 14.
    Cubo E, González M, Singer H, Mahone EM, Scahill L, Müller-Vahl KR, et al. Impact of placebo assignment in clinical trials of tic disorders. Mov Disord. 2013;28(9):1288–92.PubMedCrossRefGoogle Scholar
  15. 15.
    García-López R, Romero-González J, Perea-Milla E, Ruiz-García C, Rivas-Ruiz F, de las Mulas Béjar M. An open study evaluating the efficacy and security of magnesium and vitamin B(6) as a treatment of Tourette syndrome in children. Med Clin (Barc). 2008;131(18):689–91.CrossRefGoogle Scholar
  16. 16.
    Gabbay V, Babb JS, Klein RG, Panzer AM, Katz Y, Alonso CM, et al. A double-blind, placebo-controlled trial of ω-3 fatty acids in Tourette's disorder. Pediatrics. 2012;129(6):e1493–500.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Wu M, Xiao GH, Yao M, Zhang JM, Zhang X, Zhou YB, et al. Multicenter clinical study on the treatment of children's tic disorder with Qufeng Zhidong recipe. Chin J Integr Med. 2009;15(4):254–60.PubMedCrossRefGoogle Scholar
  18. 18.
    Wu M, Xiao GH, Zhang JM, Zhang X, Ma B, Wang SX, et al. Clinical research into Qufeng Zhidong recipe used to treat 31 children with tic disorder. J Tradit Chin Med. 2010;30(3):163–70.PubMedCrossRefGoogle Scholar
  19. 19.
    Kim YH, Son CG, Ku BC, Lee HW, Lim HS, Lee MS. Herbal medicines for treating tic disorders: a systematic review of randomised controlled trials. Chin Med. 2014;9(1):6.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Li AY, Cong S, Lu H, Li JJ, Zhao L. Clinical observation on treatment of Tourette syndrome by integrative medicine. Chin J Integr Med. 2009;15(4):261–5.PubMedCrossRefGoogle Scholar
  21. 21.
    Zhao L, Li AY, Lv H, Liu FY, Qi FH. Traditional Chinese medicine Ningdong granule: the beneficial effects in Tourette's disorder. J Int Med Res. 2010;38(1):169–75.PubMedCrossRefGoogle Scholar
  22. 22.
    Ma R, Hu SY, Tian T, Wei XW, Xiang XX, Ding Y, et al. Xifeng zhidong tablet and the placebo control treatment of tic disorder children patients of internal disturbance of Gan-wind with phlegm syndrome: a clinical study. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2014;34(4):426–30.PubMedGoogle Scholar
  23. 23.
    Zhang W, Wei L, Yu W, Cui X, Liu X, Wang Q, et al. Effect of Jian-pi-Zhi-dong decoction on striatal glutamate and γ-aminobutyric acid levels detected using microdialysis in a rat model of Tourette syndrome. Neuropsychiatr Dis Treat. 2016;12:1233–42.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Gupta S, Somkuwar S, Garg G. Clerodendron inerme: an update of its indigenous uses, phytochemistry and pharmacology. Int J Chem Sci. 2010;8(1):203–12.Google Scholar
  25. 25.
    Fan PC, Huang WJ, Chiou LC. Intractable chronic motor tics dramatically respond to Clerodendrum inerme (L) Gaertn. J Child Neurol. 2009 Jul;24(7):887–90.PubMedCrossRefGoogle Scholar
  26. 26.
    Chen HL, Lee HJ, Huang WJ, Chou JF, Fan PC, Du JC, et al. Clerodendrum inerme leaf extract alleviates animal behaviors, Hyperlocomotion, and Prepulse inhibition disruptions, mimicking Tourette syndrome and schizophrenia. Evid Based Complement Alternat Med. 2012;2012:284301.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Huang WJ, Lee HJ, Chen HL, Fan PC, Ku YL, Chiou LC. Hispidulin, a constituent of Clerodendrum inerme that remitted motor tics, alleviated methamphetamine-induced hyperlocomotion without motor impairment in mice. J Ethnopharmacol. 2015;166:18–22.PubMedCrossRefGoogle Scholar
  28. 28.
    Yu J, Ye Y, Liu J, Wang Y, Peng W, Liu Z. Acupuncture for Tourette syndrome: a systematic review. Evid Based Complement Alternat Med. 2016;2016:1834646.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Yu J, Ye Y, Li S, Liu J, Zhai Y, Zhang M, et al. The effectiveness and safety of plum-blossom needle therapy for Tourette syndrome: study protocol for a randomized controlled trial. Trials. 2015;16:320.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Nagai Y, Cavanna A, Critchley HD. Influence of sympathetic autonomic arousal on tics: implications for a therapeutic behavioral intervention for Tourette syndrome. J Psychosom Res. 2009;67(6):599–605.PubMedCrossRefGoogle Scholar
  31. 31.
    Messerotti Benvenuti S, Buodo G, Leone V, Palomba D. Neurofeedback training for tourette syndrome: an uncontrolled single case study. Appl Psychophysiol Biofeedback. 2011;36(4):281–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Hyde TM, Emsellem HA, Randolph C, Rickler KC, Weinberger DR. Electroencephalographic abnormalities in monozygotic twins with Tourette's syndrome. Br J Psychiatry. 1994;164(6):811–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Tansey MA. A simple and a complex tic (Gilles de la Tourette's syndrome): their response to EEG sensorimotor rhythm biofeedback training. Int J Psychophysiol. 1986;4(2):91–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Hampson M, Scheinost D, Qiu M, Bhawnani J, Lacadie CM, Leckman JF, et al. Biofeedback of real-time functional magnetic resonance imaging data from the supplementary motor area reduces functional connectivity to subcortical regions. Brain Connect. 2011;1(1):91–8.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Erickson MH. Experimental hypnotherapy in Tourette’s disease. Am J Clin Hypn. 1965;8:325–31.PubMedCrossRefGoogle Scholar
  36. 36.
    Young MH, Montano RJ. A new hypnobehavioral method for the treatment of children with Tourette's disorder. Am J Clin Hypn. 1988t;31(2):97–106.PubMedCrossRefGoogle Scholar
  37. 37.
    Culbertson FM. A four-step hypnotherapy model for Gilles de la Tourette's syndrome. Am J Clin Hypn. 1989;31(4):252–6.PubMedCrossRefGoogle Scholar
  38. 38.
    Lazarus JE, Klein SK. Nonpharmacological treatment of tics in Tourette syndrome adding videotape training to self-hypnosis. J Dev Behav Pediatr. 2010;31(6):498–504.PubMedGoogle Scholar
  39. 39.
    Flamand-Roze C, Célestin-Lhopiteau I, Roze E. Hypnosis and movement disorders: State of the art and perspectives. Rev Neurol (Paris). 2016;172(8–9):530–6.CrossRefGoogle Scholar
  40. 40.
    • Befort K. Interactions of the opioid and cannabinoid systems in reward: Insights from knockout studies. Front Pharmacol. 2015;6:6. This article provides detailed review of the opioid and cannabinoid systems in the brain and their roles in reinforced behaviors. PubMedPubMedCentralGoogle Scholar
  41. 41.
    Müller-Vahl KR. Treatment of Tourette syndrome with cannabinoids. Behav Neurol. 2013;27(1):119–24.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    •• Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015;313(24):2456–73. This is a systematic review of the benefits and risks of cannabinoids as medical treatment, including for TS. PubMedCrossRefGoogle Scholar
  43. 43.
    • Koppel BS. Cannabis in the Treatment of Dystonia, Dyskinesias, and Tics. Neurotherapeutics. 2015;12(4):788–92. This review highlights case reports and studies of cannabinoids for movement disorders, including tics. PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Curtis A, Clarke CE, Rickards HE. Cannabinoids for Tourette's syndrome. Cochrane Database Syst Rev. 2009;4:CD006565.Google Scholar
  45. 45.
    Jakubovski E, Müller-Vahl K. Speechlessness in Gilles de la Tourette Syndrome: Cannabis-Based Medicines Improve Severe Vocal Blocking Tics in Two Patients. Int J Mol Sci. 2017;18(8):E1739.PubMedCrossRefGoogle Scholar
  46. 46.
    Kanaan AS, Jakubovski E, Müller-Vahl K. Significant Tic Reduction in An Otherwise Treatment-Resistant Patient with Gilles de la Tourette Syndrome Following Treatment with Nabiximols. Brain Sci. 2017;7(5):E47.PubMedCrossRefGoogle Scholar
  47. 47.
    Gilbert DL, Budman CL, Singer HS, Kurlan R, Chipkin REA. D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome. Clin Neuropharmacol. 2014;37(1):26–30.PubMedGoogle Scholar
  48. 48.
    Ercan-Sencicek AG, Stillman AA, Ghosh AK, Bilguvar K, O'Roak BJ, Mason CE, et al. L-histidine decarboxylase and Tourette's syndrome. N Engl J Med. 2010;362(20):1901–8.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Baldan LC, Williams KA, Gallezot JD, Pogorelov V, Rapanelli M, Crowley M, et al. Histidine decarboxylase deficiency causes tourette syndrome: parallel findings in humans and mice. Neuron. 2014;81(1):77–90.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    •• Jankovic J. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother. 2016;17(18):2461–70. This article provides an overview of VMAT2 inhibitors and a comparison of novel agents to tetrabenazine. PubMedCrossRefGoogle Scholar
  51. 51.
    Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord. 2007;22(2):193–7.PubMedCrossRefGoogle Scholar
  52. 52.
    Chen JJ, Ondo WG, Dashtipour K, Swope DM. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clin Ther. 2012;34(7):1487–504.PubMedCrossRefGoogle Scholar
  53. 53.
    • Paton DM. Deutetrabenazine: Treatment of hyperkinetic aspects of Huntington's disease, tardive dyskinesia and Tourette syndrome. Drugs Today (Barc). 2017;53(2):89–102. This is a detailed review of deutetrabenazine, one of the novel VMAT2 inhibitors. CrossRefGoogle Scholar
  54. 54.
    Rodrigues FB, Duarte GS, Costa J, Ferreira JJ, Wild EJ. Tetrabenazine versus Deutetrabenazine for Huntington's disease: twins or distant cousins? Mov Disord Clin Pract. 2017;4(4):582–5.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    • Bashir H, Jankovic J. Treatment options for chorea. Expert Rev Neurother. 2018;18(1):51–63. This article details the efficacy of VMAT2 inhibitors for treatment of chorea. PubMedCrossRefGoogle Scholar
  56. 56.
    • Budman E, Deeb W, Martinez-Ramirez D, Pilitsis JG, Peng-Chen Z, Okun MS, Ramirez-Zamora A. Potential indications for deep brain stimulation in neurological disorders: an evolving field. Eur J Neurol. 2017 20. This is a thorough review of the current evidence for use of DBS in several neurological conditions.
  57. 57.
    • Andrade P, Visser-Vandewalle V. DBS in Tourette syndrome: where are we standing now? J Neural Transm (Vienna). 2016;123(7):791–6. This article explores the specific uses and challenges of DBS in TS. CrossRefGoogle Scholar
  58. 58.
    •• Martinez-Ramirez D, Jimenez-Shahed J, Leckman JF, Porta M, Servello D, Meng FG, Kuhn J, Huys D, Baldermann JC, Foltynie T, Hariz MI, Joyce EM, Zrinzo L, Kefalopoulou Z, Silburn P, Coyne T, Mogilner AY, Pourfar MH, Khandhar SM, Auyeung M, Ostrem JL, Visser-Vandewalle V, Welter ML, Mallet L, Karachi C, Houeto JL, Klassen BT, Ackermans L, Kaido T, Temel Y, Gross RE, Walker HC, Lozano AM, Walter BL, Mari Z, Anderson WS, Changizi BK, Moro E, Zauber SE, Schrock LE, Zhang JG, Hu W, Rizer K, Monari EH, Foote KD, Malaty IA, Deeb W, Gunduz A, Okun MS. Efficacy and Safety of Deep Brain Stimulation in Tourette Syndrome. JAMA Neurol. This study provides efficacy and safety data for a large cohort of TS patients who underwent DBS.
  59. 59.
    • Schrock LE, Mink JW, Woods DW, Porta M, Servello D, Visser-Vandewalle V, et al. Tourette syndrome deep brain stimulation: a review and updated recommendations. Mov Disord. 2015;30(4):448–71. This article provides recommendations when to consider use of DBS as treatment for TS. PubMedCrossRefGoogle Scholar
  60. 60.
    Chae JH, Nahas Z, Wassermann E, Li X, Sethuraman G, Gilbert D, et al. A pilot safety study of repetitive transcranial magnetic stimulation (rTMS) in Tourette's syndrome. Cogn Behav Neurol. 2004;17(2):109–17.PubMedCrossRefGoogle Scholar
  61. 61.
    Wu SW, Gilbert DL. Altered neurophysiologic response to intermittent theta burst stimulation in Tourette syndrome. Brain Stimul. 2012;5(3):315–9.PubMedCrossRefGoogle Scholar
  62. 62.
    Mantovani A, Lisanby SH, Pieraccini F, Ulivelli M, Castrogiovanni P, Rossi S. Repetitive transcranial magnetic stimulation (rTMS) in the treatment of obsessive-compulsive disorder (OCD) and Tourette's syndrome (TS). Int J Neuropsychopharmacol. 2006;9(1):95–100.PubMedCrossRefGoogle Scholar
  63. 63.
    Kwon HJ, Lim WS, Lim MH, Lee SJ, Hyun JK, Chae JH, et al. 1-Hz low frequency repetitive transcranial magnetic stimulation in children with Tourette's syndrome. Neurosci Lett. 2011;492(1):1–4.PubMedCrossRefGoogle Scholar
  64. 64.
    Le K, Liu L, Sun M, Hu L, Xiao N. Transcranial magnetic stimulation at 1 hertz improves clinical symptoms in children with Tourette syndrome for at least 6 months. J Clin Neurosci. 2013;20(2):257–62.PubMedCrossRefGoogle Scholar
  65. 65.
    Münchau A, Bloem BR, Thilo KV, Trimble MR, Rothwell JC, Robertson MM. Repetitive transcranial magnetic stimulation for Tourette syndrome. Neurology. 2002;59(11):1789–91.PubMedCrossRefGoogle Scholar
  66. 66.
    Landeros-Weisenberger A, Mantovani A, Motlagh MG, de Alvarenga PG, Katsovich L, Leckman JF, et al. Randomized sham controlled double-blind trial of repetitive transcranial magnetic stimulation for adults with severe Tourette syndrome. Brain Stimul. 2015;8(3):574–81.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Pediatric NeurologyThe Johns Hopkins HospitalBaltimoreUSA

Personalised recommendations